Compare MYE & COAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MYE | COAG |
|---|---|---|
| Founded | 1933 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.4B |
| IPO Year | 1995 | 2026 |
| Metric | MYE | COAG |
|---|---|---|
| Price | $34.37 | $49.66 |
| Analyst Decision | Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $26.00 | N/A |
| AVG Volume (30 Days) | ★ 428.6K | 414.0K |
| Earning Date | 05-07-2026 | N/A |
| Dividend Yield | ★ 2.71% | N/A |
| EPS Growth | ★ 389.47 | N/A |
| EPS | ★ 0.48 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $0.87 | N/A |
| Revenue Next Year | $1.83 | N/A |
| P/E Ratio | $72.96 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $15.54 | $27.47 |
| 52 Week High | $37.45 | $53.61 |
| Indicator | MYE | COAG |
|---|---|---|
| Relative Strength Index (RSI) | 64.22 | 65.32 |
| Support Level | $20.39 | $42.65 |
| Resistance Level | $35.75 | N/A |
| Average True Range (ATR) | 1.52 | 4.45 |
| MACD | 0.23 | -0.08 |
| Stochastic Oscillator | 67.22 | 87.25 |
Myers Industries Inc designs, manufactures, and markets a variety of plastic, metal, and rubber products, including a broad selection of plastic reusable containers, pallets, small parts bins, bulk shipping containers, storage and organization products, OEM parts, custom plastic products, consumer fuel containers and tanks for water, fuel and waste handling. It operates through the following segments: The Material Handling segment manufactures a selection of durable plastic reusable products that are used repeatedly during the course of their service life. The Distribution segment is engaged in the distribution of equipment, tools, and supplies used for tire servicing and automotive under-vehicle repair, etc. It generates the majority of its revenue from the Material Handling segment.
Hemab Therapeutics Holdings Inc is a clinical-stage biotechnology company developing therapies for the treatment of blood coagulation disorders. It focuses on discovering, developing, and commercializing treatments for conditions such as Glanzmann thrombasthenia, Factor VII deficiency, and von Willebrand disease. Its flagship candidate, sutacimig (HMB-001), is a bispecific antibody currently in clinical trials for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency. The company has one operating segment, engaged in the research and development of prophylactic therapeutics for bleeding disorders.